Who are Natera’s competitors?
Natera names 17 companies as competitors in its latest annual report, on 4 fronts. 2 companies name Natera back.
Skip to the field, head to head ↓Natera company profile
Natera meets a crowd in NIPT and a single primary rival in organ health
Natera's annual report for fiscal 2025 names 17 competitors, but they don't form one field. In NIPT it lists eight, from BGI to Revvity. In organ health it says, "In organ health, our primary competitor is CareDx, Inc." In oncology it lists seven, including Exact Sciences, Guardant Health and Tempus Labs. Ask who Natera's competitor is and the honest answer is: which front?
The NIPT crowd is lopsided. Quest brought in $11.0 billion, grew 12% and kept a 9% net margin. Illumina brought in $4.3 billion and kept 20%. Revvity brought in $2.9 billion and kept 8%. Natera brought in $2.3 billion, grew 36% and ran at -9%. Several of its NIPT rivals are larger and profitable. Natera is the one growing faster.
The rivalry runs both ways. Exact Sciences and Tempus AI each name Natera in their own 10-Ks. And the contest is mostly at home: revenue outside the United States was $41.8 million, 2% of the total. Natera's position is one company in three different fights, almost all of them fought in one country.
Where Natera says it competes
“Our competitors in the NIPT space include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina, through its subsidiary Verinata; Laboratory Corporation of America Holdings, or Labcorp; Myriad Genetics, Inc.; Quest Diagnostics Incorporated, or Quest; and Revvity Inc.”
“In organ health, our primary competitor is CareDx, Inc.”
“In the field of oncology, we compete with various companies that offer or seek to offer competing solutions”
“Illumina competes with us in the NIPT market through its subsidiary, Verinata.”
Who names Natera as a competitor
“We face competition from a variety of sources, including Ambry Genetics (owned by Tempus AI); Myriad Genetics, Inc.; Natera; Color Health, Inc.; GeneDx; Illumina; Variantyx; 3billion; a few large, established general testing companies such as Laboratory Corporation of America Holdings (LabCorp) and Quest Diagnostics…”
10-K for 2025“Our primary competitors for our currently marketed precision oncology tests include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Natera, Neogenomics, ResolutionBio, which was acquired by Agilent, and others.”
10-K for 2025The field, from the filings
| Company | Fiscal year | Revenue | Growth | Net margin | Employees |
|---|---|---|---|---|---|
| Natera | 2025 | $2.3B | +36% | −9% | 6,140 |
| Quest Diagnostics | 2025 | $11.0B | +12% | 9% | 57,000 |
| Illumina | 2025 | $4.3B | −1% | 20% | 8,600,501,430 |
| Exact Sciences | 2025 | $3.2B | +18% | −6% | 7,200 |
| Revvity | 2025 | $2.9B | +4% | 8% | 11,000 |
| Tempus AI | 2025 | $1.3B | +83% | −19% | 3,800 |
Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.
How concentrated Natera’s customers are
“Revenues from customers outside the United States were $41.8 million, representing 2% of total revenues for the year ended December 31, 2025.”
“For the year ended December 31, 2024, revenues from customers outside the United States were $39.2 million, representing approximately 2% of total revenues.”
“For the year ended December 31, 2023, revenues from customers outside the United States were $34.9 million, representing approximately 3% of total revenues.”
What the rivals have done lately
“On February 12, 2024, we acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million.” filing
“On June 10, 2024, we acquired select assets of PathAI Diagnostics, a business that provides anatomic and digital pathology laboratory services, in an all-cash transaction for $100 million.” filing
“As a result of the Fluent BioSciences acquisition in Q3 2024, we recorded a developed technology asset of $ 42 million, with a useful life of 7 years, and a customer relationship asset of $ 2 million, with a useful life of 11 years.” filing
“On September 12, 2023, we completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc.” filing
“This was partially offset by amortization of the intangible assets acquired as part of our acquisition of OmicEra Diagnostics, GmbH in May 2022 and Resolution Bioscience in September 2023.” filing
Asked about Natera’s competitors
Who are Natera's competitors?
In its annual report for fiscal 2025, Natera names 17 competitors across 4 fronts: nipt competitors, organ health testing competitors, oncology testing competitors and nipt market competitors. 10-K for fiscal 2025
Which companies name Natera as a competitor?
2 companies in our coverage name it in their own annual reports: Exact Sciences and Tempus AI.
How does Natera compare with its rivals?
Natera reported $2.3B in revenue in its latest fiscal year, +36% on a year, with a −9% net margin. Illumina: $4.3B, 20% net margin; Quest Diagnostics: $11.0B, 9% net margin.
What are the alternatives to Natera?
The companies Natera itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.
How much of your revenue comes from somebody who is also trying to replace you?
Sources: Natera’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.
For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.